Pseudomembranous Colitis Agents

"Pseudomembranous colitis agents" is an indication-based clinical grouping rather than a distinct pharmacological drug class It refers to antimicrobial medications used to eradicate toxin-producing *Clostridioides difficile*, the primary pathogen responsible for severe antibiotic-associated mucosal inflammation and pseudomembrane formation in the large intestine These therapies—predominantly orally administered narrow- or targeted-spectrum agents such as oral vancomycin and fidaxomicin, as well ...

It refers to antimicrobial medications used to eradicate toxin-producing *Clostridioides difficile*, the primary pathogen responsible for severe antibiotic-associated mucosal inflammation and pseudomembrane formation in the large intestine

It refers to antimicrobial medications used to eradicate toxin-producing *Clostridioides difficile*, the primary pathogen responsible for severe antibiotic-associated mucosal inflammation and pseudomembrane formation in the large intestine

These therapies—predominantly orally administered narrow- or targeted-spectrum agents such as oral vancomycin and fidaxomicin, as well as metronidazole—work by inhibiting bacterial cell-wall synthesis, RNA polymerase transcription, or DNA replication locally within the gastrointestinal tract Consequently, their primary therapeutic application is the treatment and clinical resolution of acute or recurrent *C. difficile*–associated diarrhea and pseudomembranous colitis